Despite existing reports on differential DNA methylation in type 2 diabetes (T2D) and obesity, our 104 understanding of the functional relevance of the phenomenon remains limited. Because obesity is the main 105 risk factor for T2D and a driver of methylation from previous study, we aimed to explore the effect of DNA 106 methylation in the early phases of T2D pathology while accounting for body mass index (BMI). We performed 107 a blood-based epigenome-wide association study (EWAS) of fasting glucose and insulin among 4,808 non-108 diabetic European individuals and replicated the findings in an independent sample consisting of 11,750 non-109 diabetic subjects. We integrated blood-based in silico cross-omics databases comprising genomics, 110 epigenomics and transcriptomics collected by BIOS project of the Biobanking and BioMolecular resources 111 Research Infrastructure of the Netherlands (BBMRI-NL), the Meta-Analyses of Glucose and Insulin-related 112 traits Consortium (MAGIC), the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, and 113 the tissue-specific Genotype-Tissue Expression (GTEx) project. We identified and replicated nine novel 114 differentially methylated sites in whole blood (P-value < 1.27 × 10 -7 ): sites in LETM1, RBM20, IRS2, MAN2A2 115 genes and 1q25.3 region were associated with fasting insulin; sites in FCRL6, SLAMF1, APOBEC3H genes and 116 15q26.1 region were associated with fasting glucose. The association between SLAMF1, APOBEC3H and 117 15q26.1 methylation sites and glucose emerged only when accounted for BMI. Follow-up in silico cross-omics 118 analyses indicate that the cis-acting meQTLs near SLAMF1 and SLAMF1 expression are involved in glucose level 119 regulation. Moreover, our data suggest that differential methylation in FCRL6 may affect glucose level and the 120 risk of T2D by regulating FCLR6 expression in the liver. In conclusion, the present study provided nine new DNA 121 methylation sites associated with glycemia homeostasis and also provided new insights of glycemia related loci 122 into the genetics, epigenetics and transcriptomics pathways based on the integration of cross-omics data in 123 silico. 124 125 146 Results 147 1. Blood-based epigenome-wide association analysis of glycemic traits 148
, Vincent W.V. Jaddoe 1, 14, 15 , Henning Tiemeier 1, 14, 16 , Janine F. Felix 1, 14, 17 , Audrey Y Chu 18, 19 , 4 Daniel Levy 18, 19 , Shih-Jen Hwang 18, 19 , Jan Bressler 20 , Rahul Gondalia 21 , Elias L. Salfati 22 , Christian Herder 23 Themistocles L. Assimes 22 , Lifang Hou 32, 33 , Andrea Baccarelli 34 , Eric A Whitsel 35, 36 , Ko Willems van Dijk 37, 38 , Najaf 
126
Type 2 diabetes (T2D) is a common metabolic disease, characterized by disturbances in glucose and insulin 127 metabolism, that are in part genetically driven [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] with the heritability ranging from 20% to 80% 11 . DNA 128 methylation has been associated with T2D as well as with fasting glucose and insulin 12 . Methylation-based risk 129 scores of T2D predicted incident T2D cases that go beyond traditional risk factors such as obesity and waist-hip 130 ratio 13 . Further, obesity, which is the most important determinant of insulin resistance and glucose levels in 131 the population, 14, 15 has also been associated with differential DNA methylation 13 . This raises the possibility that 132 differential methylation associated with glucose and insulin levels could be counfounded by obesity. DNA 133 methylation, mainly depending on the region, results in gene silencing and thus regulates gene expression and 134 subsequent cellular functions 16 . It is very well possible that the epigenetic modifications occur in early phases 135 of the pathology of T2D, requiring research focusing on the early process of the disease, e.g. in subjects free of 136 diabetes.
137
We aimed to determine the association of DNA methylation with fasting glucose and insulin accounting for the 138 effect of obesity in the non-diabetic subjects and to evaluate the impact of DNA methylation on cross-omics 139 level. We followed the hypothesis that genetic variants drive DNA methylation which subsequently regulates 140 gene expression and then glycemic traits, changes of which mark the early phases of diabetes pathology 141 (Figure 1a) . First, we performed a blood-based epigenome-wide association study (EWAS) meta-analysis of 142 4 ,808 diabetes-free individuals of European descent and replicated our findings among 11 cohorts summing up 143 to 11,750 trans-ethnic non-diabetic individuals, mainly from European ancestry. Subsequently, we explored 144 the role of genetics in determining the regulation of methylation associated with glycemic traits and the 145 effects of the differential methylation on the human transcriptome in silico (Figure 1a) .
resistance (HOMA-IR) and BMI 12, 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] (Supplementary Table 2 ). Of the known CpG sites, three located in 155 SLC7A11, CPT1A, and SREBF1 associated with both glucose and insulin. The remaining ten CpG sites associated 156 with insulin and were located in genes ASAM, DHCR24, RNF145, KDM2B, MYO5C, TMEM49, CPT1A, two in 157 ABCG1 and one in the 4p15.33 region.
158
The 15 novel CpGs were tested using the same models in meta-analysis of 11 independent cohorts including 159 11 
166
Because the replication cohorts also included other ethnic groups than the main European ancestry (European: 167 n = 7,254, African: n = 3,744, and Hispanic: n = 543), we also performed meta-analysis stratified by ancestry. insulin. While doing so, we centered on the 11 top independent DNA methylation sites previously identified (cg00574958 in CPT1A and cg06500161 in ABCG1 were used) and 9 novel sites from our current study (total n 184 = 20 methylation sites).
185

Genomics of the differentially methylated sites involved in glycemic traits
186
Using BIOS database (blood-based) 26 , we found that 2,991 single-nucleotide polymorphisms (SNPs) in 29 187 unique genetic loci were associated with methylation in either cis or trans across 18 unique CpG sites among 188 the tested 20 target methylation sites. For two CpG sites located in SLC7A11 and LETM1, we did not find any 189 significant meQTLs. Results are shown in Figure 2 and given in detail in Supplementary Table 4 . Seven of the 190 29 meQTLs, 5 cis-acting and 2 trans-acting were found significantly associated with T2D, fasting glucose or 191 HbA1c (shown in Figure 2 and given in detail Supplementary Table 5 ).
192
Based on our leading hypothesis, we examined whether DNA methylation may influence fasting glucose and 193 insulin in the circulation. To this end, we performed a two-sample-based Mendelian Randomization (MR) 194 analyses 30 to examine the causal effect of the differential DNA methylation sites in blood on fasting glucose or 195 insulin using the summary GWAS results from BIOS 26 and MAGIC databases 5 ( Supplementary Table 6 
Association of gene expression with differentially methylated sites in blood 204
To understand if the methylation is also eQTM, we investigated the association between gene expression and 205 the 20 key glycemic methylation sites from the European blood-based BIOS database 26 (intergrated in Figure   206 2). We found that methylation in five CpG sites, including two novel sites (in FCRL6 and SLAMF1) and three 207 known sites (in CPT1A, SREBF1 and ABCG1), was significantly negatively associated with the expression of their ). ( Supplementary Table 7) 9
Common genetic determinants of glycemia related to DNA methylation and gene expression in blood 213
We next explored if the genetic variants associated with the differential expression above were the same as 214 the meQTLs using the eQTL data from the European blood-based BIOS database 26 (integrated in Figure 2 and 215 detailed in Supplementary Table 8 ). We found three genetic determinants associated with both differential 216 DNA methylation, including two novel methylation sites (in FCRL6 and SLAMF1) and one known (in SREBF1), ).
223
Tissue-specific differential expression associated with T2D and related traits 224
We then explored the tissue-specific differential expression associated with T2D and related traits by data-225 mining from MetaXcan database from the GTEx project 28, 29 . This analyses targeted on the eQTM-related 226 expression of seven genes as shown in 2.2.1 in six glucose-metabolism-related tissues including blood, adipose 227 subcutaneous, adipose visceral omentum, liver, pancreas, and muscle skeletal (Supplementary Table 9 ). The 228 effect direction consistency was checked between methylation sites, gene expression and T2D or related traits. ) (shown in Figure 1c ). Higher liver gene expression of FCRL6, a novel locus, was associated with 236 increased risk of T2D (Z = 2.14, P-value = 0.032) based on MetaXcan 28, 29, 31 results generated by integrating 237 functional data in liver 32, 33 and the GWAS of T2D 9 . The novel cg00936728 in FCRL6 was negatively associated 238 with fasting glucose (Z = -6.17, P-value = 9.1 × 10 -8
) and expression of FCRL6 in blood (Z = -13.09, 4.0 × 10 -39 )
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The current large-scale EWAS identified and replicated nine new methylation sites associated with fasting 242 glucose or insulin, including three additionally uncovered sites (in SLAMF1, APOBEC3H and the 15q26.1 region) 243 associated with fasting glucose only after adjustment for BMI. We further validated 13 previous reported CpG 244 sites in 11 independent loci. Based on the cross-omics analyses, our report complements earlier studies 12,13,17- 245 25, 34 for multiple DNA methylation sites related to the pathology early in the development of T2D through 246 genetics and/or gene expression. We also present in silico evidence supporting the potential involvement of 247 the nine new methylation sites.
248
The novel methylation sites annotated to genes that play roles in glucose and energy metabolism (IRS2), 249 metabolism of proteins (MAN2A2 and EDEM3, the nearest gene of cg13222915), RNA and splicing regulation 250 (RBM20), RNA metabolism (APOBEC3H), small molecule transport (LETM1) and immune system process 251 (SLAMF1, FCRL6 and SV2B, the nearest gene of cg18247172). Some of these genes are also involved in other 252 diseases or biomarkers, including inflammatory phenotypes (EDEM3 with systemic lupus erythematosus 35 ,
253
SLAMF1 with inflammatory bowel disease 36 and FCRL6 with C-reactive protein (CRP) 37, 38 ), cardiovascular 254 phenotypes (RBM20 with electrocardiographic traits 39 ), cancer (IRS2 with prostate cancer 40 ) and schizophrenia 255 (MAN2A2) 41 . Thus, observations provided insight into the pathways that might link T2D to inflammation, 256 cardiovascular disease, cancer and schizophrenia, all disorders associated epidemiologically or clinically with 257 T2D. This phenomenon may point at genetic pleiotropy of the genes, i.e. a gene codes the same products in 258 various cells or have cascade-like signaling function that affects various targets.
259
In this paper, we used the assumption that genetic variants drive DNA methylation which subsequently 260 regulates gene expression and then glycemic traits 42 . Two pathways (on SREBF1 and FCRL6) related to 261 genetics-epigenetics-transcriptomics-phenotype were observed in the present study (Figure 1b and Figure1c) .
262
We validated the differential methylation of SREBF1 in insulin metabolism 43 and extended the findings building 263 a pathway based on the cascading cross-omics analysis in the assumption of genetics-epigenetics-264 transcriptomics-phenotype. We also discovered a new pathway of FCRL6 in glucose metabolism, which still 265 needs further research for its role to be fully understood. From the present study, with the integration of all 266 the significant associations, the effect allele (C) of the genetic variant rs11265282 in FCRL6 increases the 267 methylation level which associates with lower expression of FCRL6 in the blood. The decreased FCRL6 268 expression in liver was also associates with decreased risk of T2D. This presumably is mediated by a decrease 269 in fasting glucose.
The present study provides new genomic targets for further work on the pathology of T2D through large-scale 271 EWAS and replication. However, the main findings are based on data from blood which was the only accessible 272 tissue and may not be representative of more glucose-relevant tissues, although concordance of differential 273 methylation between blood and adipose is high for certain pathways 44 . Our present MR analyses yielded no 274 evidence for causality between methylation sites and fasting glucose or insulin. One limitation we faced here and granulocytes) and smoking status, and 2) a second model additionally adjusting for BMI. We removed 324 probes that have evidence of multiple mapping or contain a genetic variant in the methylation site 50 . All 325 cohort-specific EWAS results for each model were then meta-analysed using inverse variance-weighted fixed 326 effects meta-analysis as implemented in the "metafor" R package 51 . In total, we meta-analysed 403,011 CpGs 327 that passed quality control in all four discovery cohorts. The detail of the quality control for each cohort could 328 be found in the Supplementary Note. The association was later corrected by the genomic control factor (λ) in 329 each meta-EWAS 52 . We produced quantile-quantile (QQ) plots of the -log 10 (P) to evaluate inflation in the test 330 statistic (Supplementary Figure 1) . A Bonferroni correction was used to correct for multiple testing and 331 identify epigenome-wide significant results (P < 1.27 × 10 -7 ). We did not correct the number of glycemic traits 332 and models, as they are highly correlated and not independent. The genome coordinates were provided by 333 Illumina (GRCh37/hg19). The correlation of the CpG sites located in the same gene was further checked in the 334 overall RS III-1 and RS-BIOS samples by Pearson's correlation test (n = 1,544) to find the independent top CpGs.
335
For the associations discovered in the meta-EWAS that have not been reported previously, we attempted 336 replication in independent samples using the same traits and models as in the discovery analyses. Study-337 specific details of replication cohorts are provided in Supplementary Table 1 and Supplementary Note. Results 338 from each replication cohort were meta-analysed using the same methods as in the discovery analyses.
339
Bonferroni P-value < 3.3 × 10 -3 (0.05 corrected by 15 loci tested for associations) was considered significant.
340
Genomics of the differentially methylated sites and glycemic traits
341
We identified the genetic determinants of the significant CpG sites known or replicated through the current 342 EWAS using the results of the cis and trans methylation quantitative trait loci (meQTLs) from European blood-343 based BIOS database 26 adjusted for false discovery rate (FDR) less than 0.05 in the database were treated as the target genetic 348 variants in the present study. The SNPs were annotated based on the information in the previous study 26 or
We explored the associations of these DNA methylation-related SNPs with type 2 diabetes (T2D) or related 351 traits, i.e. fasting glucose, insulin, hemoglobin A1c (HbA1c), based on public genome-wide association study 352 (GWAS) datasets in European ancestry [4] [5] [6] [7] 27 . Figure 2) . Briefly, we constructed a weighted genetic risk 362 score for individual CpG on phenotype using independent SNPs as the instrument variables of the CpG, 363 implemented in the R-package "gtx". The effect of each score on phenotype was calculated as 45 . We managed to exclude the genetic loci which were genome-wide significantly associated 373 with glycemic traits, but none of the genetic loci meet this exclusion criteria. The instrumental variables that 374 explain more than 1% of variance in exposure (DNA methylation) were taken forward for MR test. The
To explore whether the differential methylation sites were associated with differential expression in blood, we explored the European blood-based BIOS database for eQTMs 26 . The significantly associated gene expression 379 probes were searched in the eQTL data in BIOS database 26 . We also investigated if the genetic variants 380 associated with these gene expression probes in blood were also related to the DNA methylation sites with 381
glycemia. Finally, we tested whether the expression of the genes that harbor the eQTMs was associated with 382 T2D and related traits in glucose metabolism-related tissues (adipose subcutaneous, adipose visceral 383 omentum, liver, whole blood, pancreas, and muscle skeletal) using MetaXcan 28, 29, 31 package. MetaXcan 384 associates the expression of the genes with the phenotype by integrating functional data generated by large-385 scale efforts, e.g Genotype-Tissue Expression (GTEx) 32, 33 with that of the GWAS of the trait. MetaXcan is 386 trained on transcriptome models in 44 human tissues from GTEx and is able to estimate their tissue-specific 387 effect on phenotypes from GWAS. For this study we used the GWAS studies of T2D 9 , fasting glucose traits 5, 6 , 388 fasting insulin 6 , hemoglobin A1c (HbA1c) 57 and homeostatic model assessment-insulin resistance (HOMA-IR) 4 .
389
We used the nominal P-value threshold (P-value = 0.05) as we had separate assumptions for each terminal 390 pathway between gene expressions and phenotype. Further, we checked the effect direction consistency of 391 the association between the methylation sites and fasting glucose or insulin with the combination of the ). NA: Not available. The gene expressions associated with the glycemia related methylation sites are shown based on the European blood-based BIOS database (n = 3,841) 26 . Locus ( The common genetic determinants of glycemia related methylation sites and gene expression in the European blood-based BIOS database (n = 3,841) 26 The significant associations between the gene expression level in the glucose metabolism-related tissue and the T2D or related traits are shown based on the tissue-specific Genotype-Tissue Expression (GTEx) project 28, 29 . It was explored in six glucose related tissues, i.e. adipose subcutaneous, adipose visceral omentum, liver, whole blood, pancreas, and muscle skeletal, and five T2D or related traits, i.e. T2D 9 , fasting glucose 5, 6 , fasting insulin 6 , HbA1c 57 , and HOMA-IR 4 . Z: effect estimate per standard error.
associations between the methylation sites and gene expression and between the gene expression and T2D
Supplementary
Supplementary Table 9 Association between the gene expression level in the glucose metabolism-related tissue and the T2D or related traits based on the Genotype-Tissue Expression (GTEx) project
Figure 1 Overview of the cross-omics analysis and examples
Cascading associations cross multiple-omics-based on different data sources were integrated in the network figures. The assumption is genetic variants drive DNA methylation which subsequently regulates gene expression and then glycemic traits. FG: fasting glucose. FI: fasting insulin. T2D: type 2 diabetes
Figure 2 Associations between genetic variants, DNA methylation sites, gene expressions and fasting glucose, insulin and related traits based on the integration of cascading associations in Figure 1a
The effect allele is standardized across all associations. Only the significant associations which passed the specific P-value threshold in each association step were shown in the figure. FG: fasting glucose. FI: fasting insulin. T2D: type 2 diabetes. 
